Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Director Gregory Bailey sold 39,430 shares of the firm’s stock in a transaction that occurred on Wednesday, December 20th. The shares were sold at an average price of $26.31, for a total transaction of $1,037,403.30. Following the sale, the director now directly owns 1,234,077 shares of the company’s stock, valued at approximately $32,468,565.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Gregory Bailey also recently made the following trade(s):

  • On Thursday, November 30th, Gregory Bailey sold 9,970 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $25.48, for a total transaction of $254,035.60.
  • On Friday, November 24th, Gregory Bailey sold 600 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $26.02, for a total transaction of $15,612.00.
  • On Monday, November 27th, Gregory Bailey sold 20,600 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $25.92, for a total transaction of $533,952.00.

Biohaven Pharmaceutical Holding Co Ltd (BHVN) traded up $0.89 on Friday, hitting $28.10. 361,698 shares of the company were exchanged, compared to its average volume of 441,944. Biohaven Pharmaceutical Holding Co Ltd has a 52 week low of $17.00 and a 52 week high of $39.51.

A number of equities research analysts have commented on BHVN shares. Zacks Investment Research raised shares of Biohaven Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Friday, September 8th. Needham & Company LLC reiterated a “buy” rating and set a $43.00 price target (up previously from $30.00) on shares of Biohaven Pharmaceutical in a research note on Wednesday, September 13th. Morgan Stanley reiterated an “overweight” rating and set a $38.00 price target (down previously from $47.00) on shares of Biohaven Pharmaceutical in a research note on Tuesday, October 3rd. Piper Jaffray Companies set a $48.00 price target on shares of Biohaven Pharmaceutical and gave the stock a “buy” rating in a research note on Monday, December 11th. Finally, BidaskClub cut shares of Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Friday, October 27th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $36.14.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Legal & General Group Plc bought a new stake in shares of Biohaven Pharmaceutical in the 3rd quarter worth about $119,000. Nationwide Fund Advisors bought a new position in Biohaven Pharmaceutical during the 3rd quarter valued at about $214,000. American International Group Inc. bought a new position in Biohaven Pharmaceutical during the 3rd quarter valued at about $251,000. State of Wisconsin Investment Board bought a new position in Biohaven Pharmaceutical during the 3rd quarter valued at about $262,000. Finally, Susquehanna International Group LLP bought a new position in Biohaven Pharmaceutical during the 3rd quarter valued at about $302,000. Institutional investors own 47.76% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Biohaven Pharmaceutical Holding Co Ltd (BHVN) Director Gregory Bailey Sells 39,430 Shares of Stock” was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://theolympiareport.com/2017/12/23/biohaven-pharmaceutical-holding-co-ltd-bhvn-director-gregory-bailey-sells-39430-shares-of-stock.html.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.